PTGX

Protagonist Therapeutics, Inc. (PTGX) | Rumor.io

Protagonist Therapeutics

PTGX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,022

Bullish sentiment (50-day avg)60%

Price to earnings ratio136.4

Market capitalization9.2B

Earnings per share1.04

Dividend yield (TTM)—

Revenue (annual)46M

Net income (annual)-130.1M

Social

What share of all stock conversation is about PTGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Mar 28

Protagonist Therapeutics' ($PTGX) ICOTYDE has shown lasting skin clearance and a favorable safety profile in once-daily pill for plaque psoriasis in Phase 3 data.
ICOTYDE achieved nearly 60% complete skin clearance and 92% PASI 90 in adolescents through Week 52, with a favorable safety profile.
Protagonist Therapeutics will present one-year Phase 3 data for ICOTYDE in moderate-to-severe plaque psoriasis at the 2026 American Academy of Dermatology Annual Meeting.

Generated by AI

Sentiment

Of the messages about PTGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +32.26	85.71% +30.73	79.09% -20.91
Bearish	0%	0% -32.26	14.29% -30.73	20.91% +20.91

Bullish· Oct 10

Protagonist Therapeutics, Inc. (PTGX) has had a significant run in the past few months, with some investors selling for a profit.
The company's pipeline looks promising, with two compounds in Phase 1 studies for obesity and a late-stage compound in partnership with J&J for immunology indications.
Analysts predict PTGX could reach $100 or more in the future, with some even suggesting a buyout in the $5-6B range.

Bearish· Apr 26

$PTGX's stock price has declined by over 50% after a clinical trial failed to meet its primary endpoint.
The failure of the high-dose oral Entyvio rival in ulcerative colitis has led to a significant drop in the stock price.
The company's 52-week low has been reached, with the stock price hitting a new low after the disappointing clinical trial results.

Generated by AI

Topics

Of the messages about PTGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	87.28%	89.42%
Analysts	0%	0%	12.13%	6.67%
Technical Analysis	0%	0%	0.59%	3.14%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.27%
Macro	0%	0%	0%	0.49%

Earnings· Mar 7

Protagonist Therapeutics, Inc. ($PTGX) reports Q4 EPS loss of $0.15 and revenue of $11.28M.
$PTGX will host its Q4 earnings call today at 4:30 PM Eastern, available to stream live or on replay.
$PTGX releases its earnings on March 7 after close.

Analysts· Oct 12

$PTGX was upgraded by JP Morgan to Overweight with a price target of $55, and by Jefferies to $60.
SVB Leerink raised its price target for $PTGX to $50 from $35, and maintained an Outperform rating.
Analysts' consensus is very bullish on $PTGX, with 7 analysts recommending a buy and a 89% buy consensus.

Announcements· Mar 18

Protagonist Therapeutics, Inc. (PTGX) has announced the FDA approval of ICOTYDE (icotrokinra) for the treatment of moderate to severe plaque psoriasis.
This approval creates an estimated $5-10 billion global market opportunity for IL-23 oral therapies in plaque psoriasis, potentially driving significant value for PTGX.
Johnson & Johnson (JNJ) has secured FDA approval for Icotyde, a major catalyst likely driving volatility for both JNJ and partner PTGX.

Technical Analysis· Oct 11

$PTGX is forming a bullish flag with a potential gap above $40 tomorrow.
The stock has significant resistance at $36 and a break above $37.50 could lead to a strong upward move.
$PTGX is building a huge flag and a break below $34.50 could lead to stops being triggered, while a breakout over today's high can be a new momentum trigger.

Generated by AI

Community

Of the messages about PTGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.74%	90.67%	71.78%	52.65%
Newcomers	5.26%	9.33%	28.22%	47.35%

Regulars· Apr 26

$PTGX is down 5.50 to 18.80, and some traders are taking profits or selling due to the decline.
There is intraday resistance at $9.40, and if $PTGX breaks above it and holds, it may be a good time to re-enter the stock.
Protagonist Therapeutics' top-line data from the Phase 2 IDEAL study of PN-943 missed the primary endpoint, causing $PTGX to decline 31% in premarket trading.

Newcomers· Apr 26

The recent Phase II ulcerative colitis readout for Protagonist Therapeutics' PN-943 did not meet the primary endpoint, causing a 30% drop in stock value.
Some newcomers are comparing Protagonist Therapeutics with other companies, such as Hemostemix, in terms of their potential for success in ulcerative colitis treatments.
A few new investors are taking a bullish stance on Protagonist Therapeutics, buying shares at lower prices, despite the company's recent setbacks.

Generated by AI

Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist Therapeutics has a market

1d agoBenzinga

The Peptide Boom That Isn’t About Your Muscles

5d agoWSJ

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

5d agobarchart.com

Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing

Dinesh V Patel, Director, President and Chief Executive Officer, on September 08, 2026, sold 125,000

19d agoYahoo Finance

Protagonist Therapeutics at Cantor conference: cash, launches and pipeline

20d agoInvesting.com

Protagonist Therapeutics CEO sells $18.2m in shares

20d agoInvesting.com

Also Discussed

Investors talking about PTGX also mention

#	Name	Attention
1	MacroGenics Inc.MGNX	0%+0
2	MORF - Morphic Holding, Inc.	——
3	MYOV - Myovant Sciences Ltd.	——
4	ASLN - ASLAN Pharmaceuticals Limited	——
5	Syndax Pharmaceuticals, Inc.SNDX	0%+0
6	Mirum Pharmaceuticals, Inc.MIRM	0%0
7	BridgeBio Pharma Inc.BBIO	0%-0.02
8	Arcturus Therapeutics Holdings Inc.ARCT	0%+0
9	Praxis Precision Medicines, Inc.PRAX	0%0
10	Atea Pharmaceuticals, Inc.AVIR	0%0

Protagonist Therapeutics, Inc.

Healthcare
Biotechnology

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases. Using a proprietary peptide technology platform, the company advances drug candidates designed to address unmet needs in inflammation and immunology, hematology, and metabolic disease. Its current programs center on differentiated medicines such as rusfertide and oral peptide candidates developed for immune-mediated and blood disorders, reflecting a strategy built around targeted mechanisms and convenient routes of administration. Protagonist Therapeutics works across research, clinical development, and collaboration-based programs to create therapies with potential use in conditions where existing treatment options are limited or inadequate. Headquartered in Newark, California, Protagonist Therapeutics plays a specialized role in the biopharmaceutical market by focusing on peptide innovation and translational medicine.

Website

Location

7707 Gateway Boulevard

Newark, CA, 94560

United States

Social

What share of all stock conversation is about PTGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Mar 28

Protagonist Therapeutics' ($PTGX) ICOTYDE has shown lasting skin clearance and a favorable safety profile in once-daily pill for plaque psoriasis in Phase 3 data.
ICOTYDE achieved nearly 60% complete skin clearance and 92% PASI 90 in adolescents through Week 52, with a favorable safety profile.
Protagonist Therapeutics will present one-year Phase 3 data for ICOTYDE in moderate-to-severe plaque psoriasis at the 2026 American Academy of Dermatology Annual Meeting.

Generated by AI

Sentiment

Of the messages about PTGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +32.26	85.71% +30.73	79.09% -20.91
Bearish	0%	0% -32.26	14.29% -30.73	20.91% +20.91

Bullish· Oct 10

Protagonist Therapeutics, Inc. (PTGX) has had a significant run in the past few months, with some investors selling for a profit.
The company's pipeline looks promising, with two compounds in Phase 1 studies for obesity and a late-stage compound in partnership with J&J for immunology indications.
Analysts predict PTGX could reach $100 or more in the future, with some even suggesting a buyout in the $5-6B range.

Bearish· Apr 26

$PTGX's stock price has declined by over 50% after a clinical trial failed to meet its primary endpoint.
The failure of the high-dose oral Entyvio rival in ulcerative colitis has led to a significant drop in the stock price.
The company's 52-week low has been reached, with the stock price hitting a new low after the disappointing clinical trial results.

Generated by AI

Topics

Of the messages about PTGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	87.28%	89.42%
Analysts	0%	0%	12.13%	6.67%
Technical Analysis	0%	0%	0.59%	3.14%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.27%
Macro	0%	0%	0%	0.49%

Earnings· Mar 7

Protagonist Therapeutics, Inc. ($PTGX) reports Q4 EPS loss of $0.15 and revenue of $11.28M.
$PTGX will host its Q4 earnings call today at 4:30 PM Eastern, available to stream live or on replay.
$PTGX releases its earnings on March 7 after close.

Analysts· Oct 12

$PTGX was upgraded by JP Morgan to Overweight with a price target of $55, and by Jefferies to $60.
SVB Leerink raised its price target for $PTGX to $50 from $35, and maintained an Outperform rating.
Analysts' consensus is very bullish on $PTGX, with 7 analysts recommending a buy and a 89% buy consensus.

Announcements· Mar 18

Protagonist Therapeutics, Inc. (PTGX) has announced the FDA approval of ICOTYDE (icotrokinra) for the treatment of moderate to severe plaque psoriasis.
This approval creates an estimated $5-10 billion global market opportunity for IL-23 oral therapies in plaque psoriasis, potentially driving significant value for PTGX.
Johnson & Johnson (JNJ) has secured FDA approval for Icotyde, a major catalyst likely driving volatility for both JNJ and partner PTGX.

Technical Analysis· Oct 11

$PTGX is forming a bullish flag with a potential gap above $40 tomorrow.
The stock has significant resistance at $36 and a break above $37.50 could lead to a strong upward move.
$PTGX is building a huge flag and a break below $34.50 could lead to stops being triggered, while a breakout over today's high can be a new momentum trigger.

Generated by AI

Community

Of the messages about PTGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.74%	90.67%	71.78%	52.65%
Newcomers	5.26%	9.33%	28.22%	47.35%

Regulars· Apr 26

$PTGX is down 5.50 to 18.80, and some traders are taking profits or selling due to the decline.
There is intraday resistance at $9.40, and if $PTGX breaks above it and holds, it may be a good time to re-enter the stock.
Protagonist Therapeutics' top-line data from the Phase 2 IDEAL study of PN-943 missed the primary endpoint, causing $PTGX to decline 31% in premarket trading.

Newcomers· Apr 26

The recent Phase II ulcerative colitis readout for Protagonist Therapeutics' PN-943 did not meet the primary endpoint, causing a 30% drop in stock value.
Some newcomers are comparing Protagonist Therapeutics with other companies, such as Hemostemix, in terms of their potential for success in ulcerative colitis treatments.
A few new investors are taking a bullish stance on Protagonist Therapeutics, buying shares at lower prices, despite the company's recent setbacks.

Generated by AI

Protagonist Therapeutics

Social

Mar 28

Bullish· Oct 10

Bearish· Apr 26

Earnings· Mar 7

Analysts· Oct 12

Announcements· Mar 18

Technical Analysis· Oct 11

Regulars· Apr 26

Newcomers· Apr 26

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Protagonist

The Peptide Boom That Isn’t About Your Muscles

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing

Protagonist Therapeutics at Cantor conference: cash, launches and pipeline

Protagonist Therapeutics CEO sells $18.2m in shares

Also Discussed

Protagonist Therapeutics, Inc.

Company Information

Location

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Protagonist

The Peptide Boom That Isn’t About Your Muscles

Polycythemia Vera Market Size, Emerging Therapies, and Forecast Insights Through 2036 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma

Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing

Protagonist Therapeutics at Cantor conference: cash, launches and pipeline

Protagonist Therapeutics CEO sells $18.2m in shares

Also Discussed

Social

Mar 28

Bullish· Oct 10

Bearish· Apr 26

Earnings· Mar 7

Analysts· Oct 12

Announcements· Mar 18

Technical Analysis· Oct 11

Regulars· Apr 26

Newcomers· Apr 26